Janssen to Showcase Growing Body of Data at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting .
- Research in Hematological Malignancies features: Ibrutinib (IMBRUVICA®), Siltuximab (SYLVANT™) and Daratumumab; Research in Solid Tumors features: Abiraterone acetate (ZYTIGA®), ARN-509, Trabectedin and JNJ-42756493 .
RARITAN, N.J., May 14, 2014 /PRNewswire/ --
Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30-June 3, 2014 in Chicago, IL. Abstracts have been accepted for presentation on hematological malignancies, prostate cancer and other solid tumors.
...
Four Trabectedin Abstracts have been Accepted for Presentation and were Sponsored by Janssen or PharmaMar:
•A phase 3 study of trabectedin (T) plus pegylated liposomal doxorubicin (PLD) versus PLD for treatment of advanced‑relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer. (Abstract TPS5612)
General poster session: Gynecologic Cancer. Saturday, May 31 at 8 a.m. CDT in S Hall A2.
Lead Author: Robert Coleman, M.D., The University of Texas MD Anderson Cancer Center, Houston, TX, USA
•Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): results from OVA-301 follow-up. (Abstract 5551)
General poster session: Gynecologic cancer. Saturday, May 31 at 8 a.m. CDT in S Hall A2.
Lead Author: Nicoletta Colombo, M.D., Ph.D., University of Milan-Bicocca, European Institute of Oncology, Milan, Italy
•Radiologic signs of adipocytic maturation (AM) in dedifferentiated liposarcoma (ddLPS) patients (pts) treated with trabectedin (T): Correlation with disease control. (Abstract 10561)
General poster session: Sarcoma. Monday, June 2 at 8 a.m. CDT in S Hall A2.
Lead Author: Sree Tirumani, M.D., Dana-Farber Cancer Institute, Boston, MA, USA
•Effects of cytochrome P450 inducer and inhibitor coadministration on the pharmacokinetics of trabectedin in patients with advanced or metastatic solid tumor. (Publication only)
Electronic publication, available on www.asco.org
Lead Author: Jean-Pascal Machiels, M.D., Ph.D., Universite Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
...